Drug Approval | January 12, 2026
FDA rejects Vanda’s jet lag drug in current form
Vanda strongly disputes the FDA’s reasoning
Vanda strongly disputes the FDA’s reasoning
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
Subscribe To Our Newsletter & Stay Updated
